<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2909">
  <stage>Registered</stage>
  <submitdate>9/09/2010</submitdate>
  <approvaldate>9/09/2010</approvaldate>
  <nctid>NCT01199809</nctid>
  <trial_identification>
    <studytitle>A Study of RO5310074 in Patients With Psoriatic Arthritis</studytitle>
    <scientifictitle>A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-001133-16</secondaryid>
    <secondaryid>PP22713</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Arthritis, Psoriatic</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - RO5310074

Experimental: 1 - 

Placebo Comparator: 2 - 


Treatment: drugs: Placebo
multiple doses

Treatment: drugs: RO5310074
multiple ascending doses

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>25 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (Cmax, t1/2, AUC, Vss, CL)</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics (anti-drug-antibodies)</outcome>
      <timepoint>25 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patients, 18 - 75 years of age

          -  Diagnosis of Psoriatic Arthritis (Moll and Wright or CASPAR criteria) of &gt;/= 6 months
             duration

          -  Have &gt;/= 3 swollen and &gt;/= 3 tender joints

          -  Inadequate response to a current or previous oral DMARD or NSAID therapy

          -  Current oral DMARDs must be at stable dose for the appropriate duration (e.g. 14 days
             for sulfasalazine and 28 days for methotrexate or oral steroids)

          -  NSAIDs up to maximum recommended dose are permitted if at stable dose for at least 14
             days prior to first dose of study drug, but not more than one NSAID simultaneously
             (except for low-dose aspirin for cardioprotection)

          -  Body mass index (BMI) 18 - 42 kg/m2 inclusive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous prolonged treatment with a biologic DMARD; use of biologic DMARD within 3
             months or 5 times its elimination half-live (whichever is longer) prior to first dose
             of study drug

          -  Previous use of B-cell depleting biologic DMARDs

          -  Any previous treatment with alkylating agents such a cyclophosphamide or chlorambucil
             or with total lymphoid irradiation

          -  History of or current inflammatory joint disease other than psoriatic arthritis; Gout
             or pseudogout that is current or has been active within the past 6 months

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  Any acquired or congenital immune deficiency or history of disease known to cause
             significant alteration in immunologic function

          -  Acute clinically significant infection in the 6 weeks prior to administration of study
             drug, history or presence of chronic infection, or history of recurrent infection as
             an adult</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>19</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital> - Melbourne</hospital>
    <hospital> - Nedlands</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, double-blind. placebo-controlled study will assess the safety, tolerability,
      pharmacokinetics and pharmacodynamics of multiple doses of RO5310074 in patients with
      psoriatic arthritis who have or have had an inadequate response to oral disease-modifying
      antirheumatic drugs (DMARDs) or non-steroidal anti-rheumatic drugs (NSAIDs). Patients will be
      randomized in cohorts to receive either 6 intravenous doses of RO5310074 or placebo.
      Anticipated time on study treatment is 12 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01199809</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>